Figure 1From: Converting tumors into vaccine manufacturing factories: DC recruitment, activation and clinical responses with a flt3L-primed in situ vaccine for low-grade lymphoma [nct01976585]Flt3L-primed insitu vaccine. A) Schema B) Regression of bulky (untreated) cervical and external iliac adenopathy and C) Decrease in peripheral blood lymphoma (included in CD19+λ-) cells with concurrent increase in non-tumor (CD+λ+) B cells.Back to article page